Cerebral Embolic Protection Devices: Are There Any Indications in Transcatheter Aortic Valve Replacement?

Although the device arm showed numerically lower rates of major adverse cardiovascular and cerebrovascular events (MACCEs) and stroke at 30 days, it did not reach statistical significance (MACCEs at 30 days: 21.7% vs. 30.8%, p = 0.34; stroke at 30 days: 2.2% vs. 5.1%, p = 0.46).

also in 111,027 other papers